Selective depletion strategies in allogeneic stem cell transplantation
- PMID: 16040390
- DOI: 10.1080/14653240510018172
Selective depletion strategies in allogeneic stem cell transplantation
Abstract
Despite improved prophylaxis and treatment, GvHD remains a major limitation to optimal allogeneic stem cell transplantation. Ex vivo selective depletion (SD) is a strategy to prevent GvHD, in which host-reactive donor lymphocytes are selectively eliminated from a PBSC allograft while useful donor immune function is preserved. The elimination of alloreactive and thereby GvHD-mediating T cells has been shown to be feasible in both pre-clinical and more recently clinical studies. However, SD techniques and the translational research needed for clinical application are still under development. Here we summarize and discuss the following aspects of the SD approach: selection of an appropriate allogeneic stimulator; the responder population; the alloresponse; methods for removal of alloreacting T cells; product testing; clinical considerations. Our review highlights the diversity of possible approaches and the need to develop different techniques for specific clinical applications.
Similar articles
-
Improving immune reconstitution while preventing GvHD in allogeneic stem cell transplantation.Cytotherapy. 2005;7(2):102-8. doi: 10.1080/14653240510027118. Cytotherapy. 2005. PMID: 16040389 Review.
-
Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin.Neoplasma. 2003;50(4):296-9. Neoplasma. 2003. PMID: 12937844
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis.Bone Marrow Transplant. 1999 May;23(10):1071-9. doi: 10.1038/sj.bmt.1701749. Bone Marrow Transplant. 1999. PMID: 10373075
-
Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.Transplantation. 2008 Nov 27;86(10):1427-35. doi: 10.1097/TP.0b013e31818810d6. Transplantation. 2008. PMID: 19034014
Cited by
-
Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.Mol Ther. 2016 Sep;24(9):1655-64. doi: 10.1038/mt.2016.147. Epub 2016 Jul 6. Mol Ther. 2016. PMID: 27401140 Free PMC article.
-
Cancer vaccines and T cell therapy.Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S97-S101. doi: 10.1016/j.bbmt.2012.09.020. Epub 2012 Oct 3. Biol Blood Marrow Transplant. 2013. PMID: 23041602 Free PMC article. Review. No abstract available.
-
Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.Expert Rev Hematol. 2012 Aug;5(4):409-25. doi: 10.1586/ehm.12.28. Expert Rev Hematol. 2012. PMID: 22992235 Free PMC article. Review.
-
Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities.Cytometry A. 2008 Nov;73(11):1043-9. doi: 10.1002/cyto.a.20594. Cytometry A. 2008. PMID: 18561198 Free PMC article. Review.
-
Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation.Biol Blood Marrow Transplant. 2013 Oct;19(10):1430-8. doi: 10.1016/j.bbmt.2013.06.019. Epub 2013 Jun 29. Biol Blood Marrow Transplant. 2013. PMID: 23819914 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical